{"id":16094,"date":"2021-02-25T13:00:38","date_gmt":"2021-02-25T12:00:38","guid":{"rendered":"https:\/\/www.izb-online.de\/?p=16094"},"modified":"2021-02-25T16:39:42","modified_gmt":"2021-02-25T15:39:42","slug":"new-cooperation-between-chromotek-and-absolute-antibody","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/new-cooperation-between-chromotek-and-absolute-antibody\/","title":{"rendered":"New cooperation between Chromotek and Absolute Antibody"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

New cooperation between Chromotek and Absolute Antibody<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Advantages of Nanobodies are combined with those of traditional antibodies: Chimeric antibodies with Nanobody binding properties[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]February 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”16086″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 ChromoTek GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Marion Jung, Managing Director ChromoTek GmbH[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Scientists have so far been able to take advantage of either Nanobodies or traditional antibodies. Advantages of Nanobodies are that they bind unique, 3-dimensional conformations of epitopes that are not recognized by traditional antibodies.\u00a0 Traditional antibodies have the property of being bivalent, meaning they have higher avidities & affinities and can be detected and captured using tools from the broad spectrum of antibody reagents, such as secondary antibodies and Nano-Secondaries. Nanobody-based chimeric antibodies combine the advantages of Nanobodies with those of traditional antibodies. This format also offers new opportunities for the pharmaceutical industry, which likes to work with traditional antibodies but is also always looking for new binding molecules.<\/p>\n

ChromoTek GmbH<\/a>, part of Proteintech specializing in Nanobody-based reagents, and Absolute Antibody Ltd.<\/a>, a leading provider of recombinant antibody technology, today announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca Nanobodies and engineered onto mouse and rabbit Fc domains to open up new research applications. Available antibodies target key fluorescent proteins commonly used as tags for protein visualization, as well as the structural protein vimentin. “We are very proud of the innovative power of ChromoTek, which now serves a global market with its innovative nanobody-based research reagents, revolutionizing research,” said Dr. Peter Hanns Zobel, managing director of the Biotechnology Innovation and Start-up Center (IZB). ChromoTek chose the IZB in Martinsried near Munich as its company headquarters.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” css=”.vc_custom_1614251069725{margin-top: 8px !important;}”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”16088″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 ChromoTek GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]HeLa cells transiently expressing Actin-Chromobody\u00ae-TurboGFP were immunostained with TurboGFP recombinant antibody, VHH-mouse IgG1 Fc fusion [CTK0204] (tbfms, 1:400) and Nano-Secondary\u00ae alpaca anti-mouse IgG1, recombinant VHH, Alexa Fluor\u00ae 647 [CTK0103, CTK0104] (sms1AF647-1, 1:500). Scale bar, 10 \u03bcM.[\/vc_column_text][vc_single_image image=”16082″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 ChromoTek GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Nanobody-based chimeric antibodies[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]The original Nanobodies, the smallest known antibody format, were generated by ChromoTek from the binding domains of alpaca heavy chain antibodies. Absolute Antibody used antibody engineering to fuse the Nanobodies onto mouse IgG1 and rabbit Fc domains, generating bivalent antibodies that extend the research applications of the original Nanobodies. For example, the engineered antibodies provide increased apparent affinity due to avidity effects in e.g. immunofluorescence experiments, as well as enable detection with different secondary antibodies to permit new co-labeling approaches. Alternatively, the engineered antibodies can be conjugated to an increased number of fluorophores for direct detection. In addition, they allow for immobilization on Protein A beads, resins or plates.<\/p>\n

The chimeric antibodies are all recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels. Available targets include the green fluorescent protein GFP, TurboGFP, and mNeonGreen, as well as an antibody targeting the structural and type III intermediate filament protein vimentin.<\/p>\n

\u201cChromoTek is proud to offer our renown Nanobodies, cited in more than 2,000 scientific publications, in new innovative formats,\u201d commented Dr. Marion Jung, CEO of ChromoTek. \u201cWe are launching these chimeric antibodies as part of Proteintech\u2019s recombinant antibody portfolio leveraging market access synergies.\u201d<\/p>\n

\u201cOur new collaboration combines ChromoTek\u2019s industry-leading Nanobody reagents with Absolute Antibody\u2019s recombinant antibody engineering expertise to offer scientists new and unique research tools,\u201d said Dr. Michael Fiebig, Vice President Product Portfolio & Innovation at Absolute Antibody. \u201cThe Nanobody-IgG fusions showcase the power of antibody engineering to open up experimental possibilities and facilitate new avenues of research.\u201d<\/p>\n

The recombinant engineered antibodies are available in both the Absolute Antibody and Proteintech catalogs. The original Nanobodies are also available via ChromoTek.<\/p>\n

About ChromoTek GmbH
\n<\/strong>ChromoTek pioneered the development and commercialization of Nanobody-based research reagents. As a market and product leader for high quality and reliable Nanobody-based reagents, we assist scientists\u2019 research world-wide. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008 ChromoTek has been acquired by Proteintech Group, Rosemont, IL in October 2020. Visit chromotek.com<\/a> and ptglab.com<\/a> for more information.<\/p>\n

About Absolute Antibody, Ltd.<\/strong>
\nAbsolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com<\/a> for more information.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n